Tests ZG006 with immunotherapy as first treatment for small cell lung cancer
Tests ZG006 with immunotherapy in adults with extensive small cell lung cancer.
Key facts
- Who runs it
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 100 people, planned
- Started
- 21 Apr 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- ZG006
- Serplulimab
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive stage small cell lung cancer who have not yet had their first treatment.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- Extensive stage small cell lung cancer, confirmed by tissue or cell tests.
Main reasons for not taking part
- The investigator decides the person is not right for the study for any reason.
- ECOG performance status higher than 1.
- Expected survival shorter than 3 months.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participants with histologically or cytologically confirmed ES-SCLC
- Fully understand the study and voluntarily sign the informed consent form
- Male or female 18~75 years of age
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1
- Life expectancy ≥ 3 months
Who cannot take part
- Participants were deemed unsuitable for participating in the study by the investigator for any reason
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in China
- Shanghai Chest HospitalShanghai, ChinaContact: Shun LuTaking people
About the trial
What the trial wants to find out
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
The 2 groups in the trial
- Part 1：Group ATreatment being tested
ZG006 Q3W
Treatment: ZG006 and Serplulimab
- Part 1：Group BTreatment being tested
ZG006 Q3W
Treatment: ZG006 and Serplulimab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Plain-language title
- Tests ZG006 with immunotherapy as first treatment for small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07231445, who can take part
- Record updated
- 28 April 2026